Kyoto University Researchers Develops Highly Effective Non-Addictive Pain Reliever
Currently, fentanyl is used for this purpose, but its intensely addictive nature poses major issues. The researchers said the new drug is non-addictive, and they aim to put it into practical use as early as 2028.
Pain relievers are divided into two categories: non-opioids, such as aspirin, which are used for mild pains, and opioids, such as fentanyl and morphine, which have incredibly stronger.
However, opioids cause side effects such as trouble breathing and addiction issues. In the United States, there have been many people who have unlawfully obtained and abused opioids, with more than 80,000 overdose deaths involving opioids in 2023.
Kyoto University Prof. Masatoshi Hagiwara and Associate. Prof. Masayasu Toyomoto focused on noradrenaline, a neurotransmitter that suppresses pain. They found a compound in a database that increases the secretion of noradrenaline and named it 'Adriana.' When this compound was administered to mice and monkeys, it was found to have pain-relieving effects comparable to those of opioids, without causing respiratory distress or dependence.
In addition, a clinical trial was conducted at Kyoto University Hospital involving 20 patients who had undergone lung cancer surgery, yielding promising results. Hagiwara said, 'If this compound is put into practical use, it can largely contribute to the reduction of opioid use in medical settings.' The team is scheduled to conduct a clinical trial involving hundreds of participants in the United States as early as next year.
'If the pain reliever demonstrates efficacy in treating chronic pain that is difficult to treat, it has the potential for widespread use,' said Makoto Tsuda, a professor at Kyushu University and a neuropharmacology expert.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tokyo Weekender
an hour ago
- Tokyo Weekender
New Mineral Discovered in Japan Named After Sun Goddess Amaterasu
Scientists in Japan have uncovered a new mineral hidden inside jadeite, the country's nationally designated stone. Named Amaterasuite after the sun goddess Amaterasu in Shinto mythology, the discovery was made by a joint team from the University of Tokyo, Yamaguchi University, Kyoto University, the Japan Synchrotron Radiation Research Institute, Rigaku Corporation and two amateur mineral collectors. The specimen came from jade deposits in the Osayama mountain area of Okayama Prefecture — a site not usually associated with rare mineral finds. A photo of Jadeite Hidden Within a Gem Amaterasuite is unlike any mineral previously documented. Its chemical formula combines strontium, titanium, silicon, oxygen, hydrogen and chlorine in a unique ratio, suggesting the presence of geological processes previously unknown to science. The mineral was found within jade, which is primarily made of jadeite. Jadeite forms under intense pressures in subduction zones, where tectonic plates collide and descend into the Earth's mantle. These extreme conditions not only produce jade's distinctive toughness and beauty but also make it a geological archive of the Earth's tectonic history. Jade — called hisui in Japanese — also holds special cultural status in Japan, having been used for tools, ornaments and ceremonial items for thousands of years. Its significance led to jade being named the country's national stone in 2016 by the Japan Association of Mineralogical Sciences. While other new minerals have been found in jade from Niigata Prefecture's Itoigawa region, Amaterasuite marks the first discovery of its kind in deposits found in Okayama Prefecture. Amaterasu: The Sun Goddess The mineral's name pays tribute to Amaterasu, the sun goddess and one of the most revered deities in Japanese mythology . She is a central figure in the Kojiki and Nihon Shoki , Japan's oldest historical chronicles, and is believed to be the mythical ancestor of Japan's imperial family. As ruler of the heavens, Amaterasu embodies light, order and renewal. One of her most famous legends recounts how, after a quarrel with her storm god brother Susanoo no Mikoto, Amaterasu hid inside a cave, plunging the world into darkness. The other gods lured her out through a raucous celebration, restoring sunlight to the land. This myth is often interpreted as a symbol of rebirth and the return of hope. Discover Tokyo, Every Week Get the city's best stories, under-the-radar spots and exclusive invites delivered straight to your inbox. By signing up, you agree to our Privacy Policy . Related Posts Japanese Mythology: The Shinto Creation Myth The Real-Life Locations Behind 3 Iconic Japanese Myths Japanese Scientists Develop Artificial Blood Compatible With All Blood Types
Yomiuri Shimbun
3 days ago
- Yomiuri Shimbun
Kyoto University Researchers Develops Highly Effective Non-Addictive Pain Reliever
A team of Kyoto University researchers has announced that they have found a powerful painkiller candidate that can alleviate the severe pain of cancer patients without major negative side effects. Currently, fentanyl is used for this purpose, but its intensely addictive nature poses major issues. The researchers said the new drug is non-addictive, and they aim to put it into practical use as early as 2028. Pain relievers are divided into two categories: non-opioids, such as aspirin, which are used for mild pains, and opioids, such as fentanyl and morphine, which have incredibly stronger. However, opioids cause side effects such as trouble breathing and addiction issues. In the United States, there have been many people who have unlawfully obtained and abused opioids, with more than 80,000 overdose deaths involving opioids in 2023. Kyoto University Prof. Masatoshi Hagiwara and Associate. Prof. Masayasu Toyomoto focused on noradrenaline, a neurotransmitter that suppresses pain. They found a compound in a database that increases the secretion of noradrenaline and named it 'Adriana.' When this compound was administered to mice and monkeys, it was found to have pain-relieving effects comparable to those of opioids, without causing respiratory distress or dependence. In addition, a clinical trial was conducted at Kyoto University Hospital involving 20 patients who had undergone lung cancer surgery, yielding promising results. Hagiwara said, 'If this compound is put into practical use, it can largely contribute to the reduction of opioid use in medical settings.' The team is scheduled to conduct a clinical trial involving hundreds of participants in the United States as early as next year. 'If the pain reliever demonstrates efficacy in treating chronic pain that is difficult to treat, it has the potential for widespread use,' said Makoto Tsuda, a professor at Kyushu University and a neuropharmacology expert.
Yomiuri Shimbun
6 days ago
- Yomiuri Shimbun
Researchers Find Link between Gene, Pancreatic Cancer Malignancy
KYOTO (Jiji Press) — Researchers mainly from Kyoto University have found that impaired function of a specific gene contributes to the malignancy of pancreatic cancer, which is hard to treat with chemotherapy. They said that the reduced gene function increases a protein that promotes metastasis and that existing drugs may be effective in suppressing the protein's functions. The finding was published in the Journal of Clinical Investigation in June. Pancreatic cancer is the third leading cause of cancer death in Japan. The five-year survival rate is 8.5%, the worst among any cancer. Malignant cases account for 30% to 40%, but the underlying mechanisms had not been well understood. The team examined pancreatic cancer tissue removed during surgery and found that the decline in function of Polybromo 1, or PBRM1, a gene that regulates the expression of various proteins, is linked to greater malignancy and a higher risk of relapse. A genetic modification to disable PBRM1 in mice with pancreatic cancer resulted in a higher malignancy rate, increased metastases and shorter survival. The cancer cells showed an increased level of vimentin, a protein that promotes metastasis. Meanwhile, the malignancy rate and metastases decreased after mice were given a drug that suppresses vimentin. Such correlations were also confirmed in human pancreatic cancer. The research 'has shown that drugs to suppress vimentin effects may lead to a new treatment for highly malignant pancreatic cancer,' Kyoto University associate professor Akihisa Fukuda said. 'We hope to conduct clinical trials to realize early practical application.'
